Previous studies have shown that prior glucocorticoid therapy, decreased CD4+ T-cell count, and increased 1,3-β-D-glucan level are risk factors for PJP in patients with CTD-ILD [6, 24]. The gene discussed is CD4; the disease is pneumocystosis.